论文部分内容阅读
目的：探讨血液肿瘤患者红细胞免疫遗传缺陷规律。方法：用红细胞CR1密度基因组PCR加HindⅢ酶切技术，对41例血液肿瘤患者进行研究。结果：发现血液肿瘤患者红细胞CR1密度基因组的一个点突变率为33．3％，明显高于正常人（18．0％），P＜0．05，尤其是女性患者1个点突变和2个点突变的比率明显高于男性，P＜0．01。结论：证实了部分血液肿瘤患者可能存在红细胞的免疫遗传缺陷。
Objective: To investigate the genetic defect of red blood cells in patients with hematological tumors. METHODS: A total of 41 hematological cancer patients were studied using the red cell CR1 density genome PCR plus HindIII enzyme digestion. RESULTS: A point mutation rate of the erythrocyte CR1 density genome was found to be 33.3% in patients with hematological malignancy, which was significantly higher than that in normal subjects (18.0%), P<0.05, especially in female patients with 1 point mutation and 2 The rate of point mutations was significantly higher than that of men, P<0.01. Conclusion: It was confirmed that some blood tumor patients may have immune genetic defects of red blood cells.